<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603159</url>
  </required_header>
  <id_info>
    <org_study_id>Capecitabine and esophageal</org_study_id>
    <nct_id>NCT02603159</nct_id>
  </id_info>
  <brief_title>Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy</brief_title>
  <acronym>DCECRT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Henan University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Henan University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Definitive chemoradiotherapy with cisplatin with cisplatin plus 5-fluorouracil is the
      standard in Western countries in esophagus cancer.But in China because of its toxic reaction,
      most of patients stop the halfway.Because low toxicity, Capecitabine is widely used in the
      chemotherapy of esophageal cancer.

      The purpose of this experiment was to study the different cycle on capecitabine with
      chemotherapy for esophageal cancer chemoradiation effect.We are prepared to within 2 years
      study recruited 200 patients with esophageal cancer.The primary endpoint is overall survival
      and the secondary endpoints include progression-free survival, response rate,pathologic
      complete response rate and adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We recruited the patients who were pathologically confirmed with esophageal squamous cell
      carcinoma from the Oct 2014. The the patients was divided into two groups. Group 1:
      Capecitabine + chemoradiation, radiation at the end of the stop using capecitabine. Group 2:
      Capecitabine + chemoradiation, at the end of the radiotherapy with capecitabine consolidating
      treatment for 5 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival, OS</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall remission rate, ORR</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious adverse event</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life, Qol</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response rate</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stage III Esophageal Squamous Cell Carcinoma</condition>
  <condition>Stage II Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Capecitabine-5 weeks-radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine 5 weeks : 625mg/m2, bid d1-5; q1w, po,5 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine-10 weeks-radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine 10 weeks : 625mg/m2, bid d1-5; q1w, po,10 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine(Aibin)</intervention_name>
    <description>Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total</description>
    <arm_group_label>Capecitabine-5 weeks-radiotherapy</arm_group_label>
    <arm_group_label>Capecitabine-10 weeks-radiotherapy</arm_group_label>
    <other_name>Aibin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity</description>
    <arm_group_label>Capecitabine-5 weeks-radiotherapy</arm_group_label>
    <arm_group_label>Capecitabine-10 weeks-radiotherapy</arm_group_label>
    <other_name>radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 45-75years old

          -  Histologically proven squamous cell carcinoma of the esophagus

          -  the tumor was in T2-4N0-2M0

          -  The patients have not received the surgery or chemo-radiotherapy.

          -  Hb≥80g/L, absolute neutrophil count ≥1.5×109/L, Plt≥90×109/L,

          -  ALT、AST≤2.5*N,Cr≤1.5*N.

          -  performance status score 0-2

        Exclusion Criteria:

          -  pregnant, lactating women

          -  Oxaliplatin or fluorouracil Allergy or metabolic disorders

          -  Radiotherapy contraindications

          -  History of organ transplantation

          -  Brain metastasis

          -  The peripheral nervous system disorders

          -  Severe infection

          -  Oral capecitabine who have difficulty with,such as dysphagia,The activities of
             digestive ulcer, Gastrointestinal bleeding

          -  Severe chronic diseases, such as, hepatopathy, nephropathy, respiratory disease,high
             blood pressure, diabetes.

          -  Other malignant tumor in recent 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shegan Gao, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanyou Shan, Master</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoshan Feng, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiachun Sun, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xinshuai Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guoqiang Kong, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaozhi Yuan, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruinuo Jia, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Zhuo, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jing Ren, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruina Yang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yali Zhang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongxuan Liu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Wang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Wang, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weijiao Yin, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shiyuan Song, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shegan Gao, Doctor</last_name>
    <phone>18638859977</phone>
    <email>gsg112258@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tanyou Shan, Master</last_name>
    <phone>18537976669</phone>
    <email>shantanyou@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shegan gao, doctor</last_name>
      <phone>0379 64811906</phone>
      <email>gsg112258@163.com</email>
    </contact>
    <contact_backup>
      <last_name>tanyou shan, master</last_name>
      <phone>0379 64815350</phone>
      <email>shantanyou@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):691-7. doi: 10.1016/j.ijrobp.2010.06.041. Epub 2010 Oct 1.</citation>
    <PMID>20888705</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>November 9, 2015</last_update_submitted>
  <last_update_submitted_qc>November 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Esophageal Squamous Cancer</keyword>
  <keyword>Capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

